CD4 and neoplasm: BBR@IR68-Lip can significantly inhibit tumor growth in CT26 tumor models; downregulate the expression of PD-L1 and IDO1 protein; effector T cell infiltration (CD4+ T cells, CD8+ T cells ↑);